Cover Image
市場調查報告書

功能性(非潰瘍)消化不良 : 開發平台分析

Functional (Non Ulcer) Dyspepsia - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 251518
出版日期 內容資訊 英文 45 Pages
訂單完成後即時交付
價格
Back to Top
功能性(非潰瘍)消化不良 : 開發平台分析 Functional (Non Ulcer) Dyspepsia - Pipeline Review, H2 2016
出版日期: 2016年07月20日 內容資訊: 英文 45 Pages
簡介

所謂非潰瘍消化不良是在表示原因不明的消化不良的前兆·症狀所用的用語。同時也被稱為機能性消化不良及非潰瘍胃痛。主要的前兆·症狀有下胸部和腹上部的灼熱感及不適(可靠用餐和製酸藥控制),飽脹感,打嗝,噁心等。易罹病素質有過量攝取咖啡因和酒精,抽煙,攝取特定藥物──部分OTC止痛藥(阿斯匹林,ibupurofen(advil,motrin及其它)),對胃有副作用的東西──等。主要治療藥有抗生素和抗憂鬱劑等。

本報告提供全球各國治療功能性(非潰瘍)消化不良所用的開發中產品之開發情形相關分析,提供您產品開發·上市的最新趨勢,及臨床實驗的各階段產品一覽,主要企業簡介,主要藥物概要,最新的產業趨勢等資訊。

目錄

簡介

  • 分析範圍

功能性(非潰瘍)消化不良概要

治療藥的開發

  • 功能性(非潰瘍)消化不良開發中產品:概要
  • 功能性(非潰瘍)消化不良開發中產品:比較分析

各企業開發中的功能性(非潰瘍)消化不良治療藥

大學/研究機關研究中的功能性(非潰瘍)消化不良治療藥

開發中產品的概要

  • 後期階段的產品
  • 臨床實驗階段的產品
  • 初期階段的產品

功能性(非潰瘍)消化不良治療藥:開發中的產品一覽(各企業)

功能性(非潰瘍)消化不良治療藥:研究中的產品一覽(大學/研究機關別)

功能性(非潰瘍)消化不良開發治療藥的企業

  • Almirall, S.A.
  • Eisai
  • Ironwood Pharmaceuticals, Inc.
  • RaQualia Pharma Inc.
  • Zensun (Shanghai) Sci & Tech Co., Ltd.
  • Zeria Pharmaceutical Co Ltd

功能性(非潰瘍)消化不良:治療藥的評估

  • 單劑治療藥的情況
  • 標的別
  • 各作用機制
  • 各投藥法
  • 各分子類型

藥物簡介

  • acotiamide hydrochloride
    • 產品概要
    • 功能機制
    • 研究開發(R&D)的發展情形
  • cinitapride
  • IW-9179
  • rabeprazole sodium DR
  • RQ-00000010
  • RQ-00201894
  • Small Molecule to Activate 5-HT1 Receptor for Constipation and Dyspepsia
  • ZS-07

功能性(非潰瘍)消化不良治療藥:開發中產品的最新趨勢

功能性(非潰瘍)消化不良治療藥:開發暫停的產品

功能性(非潰瘍)消化不良治療藥:開發中止的產品

功能性(非潰瘍)消化不良相關產品的開發的里程碑

  • 值得注意的最新趨勢·新聞稿

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8251IDB

Summary

Global Markets Direct's, 'Functional (Non Ulcer) Dyspepsia - Pipeline Review, H2 2016', provides an overview of the Functional (Non Ulcer) Dyspepsia pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Functional (Non Ulcer) Dyspepsia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Functional (Non Ulcer) Dyspepsia and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Functional (Non Ulcer) Dyspepsia
  • The report reviews pipeline therapeutics for Functional (Non Ulcer) Dyspepsia by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Functional (Non Ulcer) Dyspepsia therapeutics and enlists all their major and minor projects
  • The report assesses Functional (Non Ulcer) Dyspepsia therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Functional (Non Ulcer) Dyspepsia

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Functional (Non Ulcer) Dyspepsia
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Functional (Non Ulcer) Dyspepsia pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Functional (Non Ulcer) Dyspepsia Overview
  • Therapeutics Development
    • Pipeline Products for Functional (Non Ulcer) Dyspepsia - Overview
    • Pipeline Products for Functional (Non Ulcer) Dyspepsia - Comparative Analysis
  • Functional (Non Ulcer) Dyspepsia - Therapeutics under Development by Companies
  • Functional (Non Ulcer) Dyspepsia - Therapeutics under Investigation by Universities/Institutes
  • Functional (Non Ulcer) Dyspepsia - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • Functional (Non Ulcer) Dyspepsia - Products under Development by Companies
  • Functional (Non Ulcer) Dyspepsia - Products under Investigation by Universities/Institutes
  • Functional (Non Ulcer) Dyspepsia - Companies Involved in Therapeutics Development
    • Ironwood Pharmaceuticals, Inc.
    • RaQualia Pharma Inc.
    • Yuhan Corporation
    • Zensun (Shanghai) Sci & Tech Co., Ltd.
    • Zeria Pharmaceutical Co., Ltd.
  • Functional (Non Ulcer) Dyspepsia - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • 5-BIOP - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • acotiamide hydrochloride - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • LT-4005 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • recanaclotide - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • RQ-00000010 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • RQ-00201894 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • YH-12852 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ZS-07 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Functional (Non Ulcer) Dyspepsia - Dormant Projects
  • Functional (Non Ulcer) Dyspepsia - Discontinued Products
  • Functional (Non Ulcer) Dyspepsia - Product Development Milestones
    • Featured News & Press Releases
      • Oct 20, 2014: Ironwood Presents IW-9179 Phase IIa Data at American College of Gastroenterology 2014 Annual Scientific Meeting
      • Mar 25, 2013: Zeria Pharma Receives Approval For Acofide In Japan For Treating Functional Dyspepsia
      • Feb 29, 2012: RaQualia Pharma Receives MHRA Approval To Initiate First-In-Human Study For 5-HT4 Partial Agonist RQ-00000010
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Functional (Non Ulcer) Dyspepsia, H2 2016
  • Number of Products under Development for Functional (Non Ulcer) Dyspepsia - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Investigation by Universities/Institutes, H2 2016
  • Functional (Non Ulcer) Dyspepsia - Pipeline by Ironwood Pharmaceuticals, Inc., H2 2016
  • Functional (Non Ulcer) Dyspepsia - Pipeline by RaQualia Pharma Inc., H2 2016
  • Functional (Non Ulcer) Dyspepsia - Pipeline by Yuhan Corporation, H2 2016
  • Functional (Non Ulcer) Dyspepsia - Pipeline by Zensun (Shanghai) Sci & Tech Co., Ltd., H2 2016
  • Functional (Non Ulcer) Dyspepsia - Pipeline by Zeria Pharmaceutical Co., Ltd., H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Functional (Non Ulcer) Dyspepsia - Dormant Projects, H2 2016
  • Functional (Non Ulcer) Dyspepsia - Discontinued Products, H2 2016

List of Figures

  • Number of Products under Development for Functional (Non Ulcer) Dyspepsia, H2 2016
  • Number of Products under Development for Functional (Non Ulcer) Dyspepsia - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Targets, H2 2016
  • Number of Products by Stage and Targets, H2 2016
  • Number of Products by Mechanism of Actions, H2 2016
  • Number of Products by Stage and Mechanism of Actions, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top